在性结肠炎中停止使用乌斯特基努马布的现实有效性和风险因素
Genta Uchida1,2, Masanao Nakamura3, Takeshi Yamamura2
1Department of Gastroenterology and Hepatology, Toyota Kousei Hospital, Toyota, Japan.
乌斯特基努马布 (UST) 在现实实践中有效治疗性结肠炎 (UC). 高基线C反应蛋白 (CRP) 水平预测治疗中止,帮助UC患者的临床决策.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌斯特基努马布 (UST) 已批准用于中度至重度的性结肠炎 (UC).
- 在日常临床实践中,实践数据对于验证UST的有效性和安全性至关重要.
- 有限的研究证实了UST在UC患者的实际有效性.
研究的目的:
- 评估UST在UC患者的短期和长期有效性.
- 评估UST的耐用性,安全性,并确定停止使用的风险因素.
- 为优化UC中UST治疗策略提供现实世界的证据.
主要方法:
- 对31名用UST治疗的UC患者进行了回顾性,单中心的观察性研究.
- 主要结局:在2至8周和24至48周的临床缓解率.
- 二级结局:临床反应,治疗持久性,内镜变化,不良事件和使用利希泰格评分的停药预测指标.
主要成果:
- 在第48周,临床缓解率达到64.5%.
- 38%的患者停止了UST,主要是由于初级失败 (75.0%).
- 基线高C-反应蛋白 (CRP) 是中止的重要风险因素;没有报告任何不良事件.
结论:
- 乌斯特基努马布在现实环境中证明了治疗性结肠炎的有效性.
- 基线CRP水平升高是UST治疗失败的关键预测因素.
- 识别停止治疗的风险因素,如高CRP,可以指导临床医生选择适当的UC疗法.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
